Want to submit your event or news story?
For nearly three decades, Grace John-Stewart, a professor of global health and epidemiology at the University of Washington School of Public Health, has devoted her career to improving HIV prevention and treatment.
Dear DGH community,
We are reaching out in support and solidarity as we reel from recent events. Today, supporters of President Trump violently entered the US Capitol and disrupted the counting of certified electoral votes, encouraged by the President’s false claims of election fraud. The disruption of our democratic process in Washington, DC and the violence we are witnessing are deeply disturbing. We recognize that these scenes may be distressing, especially to members of our community who have lived through coups and civil unrest.
BY EMILY BOYNTON. Right as Rain, UW Medicine
First-generation students are typically defined as first in their family to obtain a bachelor’s degree. Being a first generation student, who doesn't have a family history of higher education, takes courage and determination and is an identity to be proud of.
In the Media
Even partial protection of one dose could be enough to slow the spread of the virus, the UW Medicine researchers argue in a paper.
MEDIA CONTACT: Susan Gregg - 206.616.6730, firstname.lastname@example.org
Giving one dose of the COVID-19 vaccines currently approved in the United States could curtail the spread of the SARS-CoV-19 in the community more quickly than the recommended two doses, say two vaccine experts at the University of Washington School of Medicine.
UW Medicine Researchers Conducting Phase 3 Trial of Novavax COVID-19 Vaccine (quotes Scott McClelland)
By Brian Flores, Q13 FOX
SEATTLE - The race to develop and administer a COVID-19 vaccine continues. It comes as scientists are predicting an increase in COVID cases from the holidays.
The glimmer of hope, however, comes in the form of these vaccines. Pfizer and Moderna's versions are being rolled out to healthcare workers and people 65-years-old and older, but Maryland-based Novavax is currently conducting its Phase III trial on their COVID-19 vaccine.